antibody

SPG33 Antibody

MBS853754

0.1 mg

290 USD

polyclonal

rabbit

nonconjugated

human, mouse, rat

western blot, immunohistochemistry

Antibody

SPG33 Antibody

SPG33

Homo sapiens zinc finger, FYVE domain containing 27 (ZFYVE27), transcript variant 1, mRNA; Protrudin; protrudin; zinc finger, FYVE domain containing 27; Zinc finger FYVE domain-containing protein 27

SPG33

ZFYVE27; ZFYVE27; SPG33; PROTRUDIN

ZFY27_HUMAN

Polyclonal

Rabbit

Human, Mouse, Rat

3046

Lyophilized anti-SPG33 antibody purified by peptide affinity column containing 1% BSA and 0.02% NaN3

100ug/200ul

Already reconstituted in 200ul sterile H2O. The antibody is stable for at least one year when stored at -20 degree C after reconstitution. Avoid repeated freeze/defrost cycles.

Western Blot (WB), Immunohistochemistry (IHC)

Peptide ELISA titer: 1:40,000-1:80,000. Western blot analysis: 1:200-1:500. Immunohistochemistry: 1:50-1:500. Optimal dilutions/concentrations should be determined by the end user.

Source Note: Rabbit polyclonal SPG33(1) antibody was raised against a 16 amino acid peptide from near the C terminal residues of human SPG33 protein. Reactivity Note: Not yet tested in other species.

Pathway: zinc finger, FYVE domain containing 27

Cancer; Cardiovascular; Cell Biology; Epigenetics & Nuclear Signaling; Developmental Biologys; Immunology; Drug Discovery Products; Metabolism; Neuroscience; Signal Transduction; Stem Cells; Autophagy antibody

172072639

NP_001002261.1

NM_001002261.2

41,417 Da

This gene encodes a protein with several transmembrane domains, a Rab11-binding domain and a lipid-binding FYVE finger domain. The encoded protein appears to promote neurite formation. A mutation in this gene has been reported to be associated with hereditary spastic paraplegia, however the pathogenicity of the mutation, which may simply represent a polymorphism, is unclear. [provided by RefSeq, Mar 2010]

ZFYVE27: Functions as an upstream inhibitor of RAB11, regulating directional protein transport to the forming neurites. Involved in nerve growth factor-induced neurite formation. May have a more general role in cell projections formation. Defects in ZFYVE27 are the cause of spastic paraplegia autosomal dominant type 33 (SPG33). Spastic paraplegia is a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. According to PubMed:18606302, the properties of the variant Val-191 and its frequency in some populations raise doubts on the implication of that gene in the disease. 5 isoforms of the human protein are produced by alternative splicing. Protein type: Cytoskeletal; Membrane protein, multi-pass; Membrane protein, integral. Chromosomal Location of Human Ortholog: 10q24.2. Cellular Component: endoplasmic reticulum membrane; recycling endosome membrane; axon; endoplasmic reticulum; dendrite; integral to membrane. Molecular Function: protein binding; metal ion binding. Biological Process: nerve growth factor receptor signaling pathway; neurite development. Disease: Spastic Paraplegia 33, Autosomal Dominant

0.1 mg

290 USD